Law Firm Opens Investigation Into KDDI Over Delayed Earnings Disclosure

BenzingaBenzinga
|||1 min read
Key Takeaway

Rosen Law Firm investigates KDDI for delayed earnings disclosure and potential securities violations. Stock fell 11.4% following announcement of internal investigation.

Law Firm Opens Investigation Into KDDI Over Delayed Earnings Disclosure

Rosen Law Firm has initiated an investigation into potential securities violations by KDDI Corporation, citing concerns over materially misleading business disclosures. The investigation was prompted by the Japanese telecommunications company's decision to postpone its earnings report release due to an ongoing internal investigation, raising questions about the adequacy and timeliness of the company's public communications regarding material business developments.

KDDI's stock experienced a significant decline, falling 11.4% on February 6, 2026, following the announcement of the delayed earnings disclosure. The market reaction underscores investor concern regarding the nature of the internal investigation and potential implications for the company's financial performance and corporate governance practices.

Investors who purchased KDDI securities during the relevant period are being encouraged to contact the firm to discuss their legal rights and potential remedies. Class action litigation, typically structured on a contingency fee basis, may provide an avenue for affected shareholders to seek compensation for losses incurred as a result of the alleged disclosure violations.

Source: Benzinga

Back to newsPublished Feb 12

Related Coverage

GlobeNewswire Inc.

Inovio Investors Face April 7 Deadline in Securities Class Action Over Alleged Misstatements

Rosen Law Firm alerts $INO investors of April 7, 2026 deadline to join class action over alleged false statements regarding manufacturing and regulatory prospects.

INO
GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX
GlobeNewswire Inc.

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

NKTR